Synopsis: CSRC Think Tank: Real World Data to Assess Cardiovascular Safety- Can We Improve Efficiencies in Phase 3 Development Posted on December 12, 2016December 12, 2016 by csrc View the paper HERE
Practical Considerations for Assessing Cardiac Repolarization of Diabetes Drugs. Leader: Ingrid Hensley Posted on November 25, 2014July 25, 2016 by csrc
How Can the TQT Study Be Replaced? The Role of Concentration Effect Modeling in QT Assessment. Leader: Borje Darpo Posted on November 25, 2014July 25, 2016 by csrc
Designs and statistical approaches to assess CV risk of new type 2 diabetes therapies in development. Leader: Mary Jane Geiger Posted on November 25, 2014July 25, 2016 by csrc
Hess C, et al. TransRadial Education And Therapeutics (TREAT): Shifting the balance of safety and efficacy of antithrombotic agents in percutaneous coronary intervention. A report from the Cardiac Safety Research Consortium. Am Heart J. 2013; 165(3) : 344-353 Posted on November 25, 2013July 25, 2016 by csrc View Paper Here
Christian J, et al. Cardiac Imaging for the Evaluation of Drug Induced Cardiotoxicity. Am Heart J. 2012; 164(6) : 846-855 Posted on August 13, 2012July 25, 2016 by csrc View Paper Here
Kligfield P, et al. Cardiac Safety Research Consoritum ECG Warehouse: Database specifications and principles of use for algorithm development and testing. Am Heart J. 2010; 160(6):1023-1028 Posted on August 13, 2010July 7, 2016 by csrc View Paper Here
Al-Khatib SM, et al. Planning the safety of atrial fibrillation ablation registry initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: A cardiac safety research consortium “incubator” think tank. Am Heart J. 2010; 159(1): 17-24 Posted on August 13, 2010July 7, 2016 by csrc View Paper Here
